Anaphylaxis Risk with Ferinject (Ferric Carboxymaltose)
Anaphylaxis to Ferinject is very rare, occurring in approximately 0.8 cases per 10,000 first administrations (0.008%), making it one of the safest intravenous iron formulations currently available. 1
Quantified Risk Data
The most robust comparative safety data comes from a large Medicare retrospective cohort study analyzing over 200,000 patients receiving their first IV iron administration. Ferric carboxymaltose (Ferinject) demonstrated the lowest adjusted incidence rate of anaphylaxis among all IV iron products studied 1:
- Ferric carboxymaltose: 0.8 cases per 10,000 administrations (95% CI: 0.3-2.6)
- Iron sucrose: 1.2 cases per 10,000 administrations
- Ferric gluconate: 1.5 cases per 10,000 administrations
- Ferumoxytol: 4.0 cases per 10,000 administrations
- Iron dextran: 9.8 cases per 10,000 administrations
This translates to an 8-fold lower risk compared to iron dextran and a 3-fold lower risk compared to ferumoxytol 1.
Broader Hypersensitivity Reactions
While true anaphylaxis is exceedingly rare, minor infusion reactions occur in approximately 1-3% of patients across all modern IV iron formulations when administered properly 2. These reactions are typically mild and self-limited, not representing true anaphylaxis.
Recent comparative data shows ferric carboxymaltose has favorable safety compared to other formulations:
- No anaphylaxis cases reported in a head-to-head randomized trial of 1,000 patients receiving ferric carboxymaltose versus 997 receiving ferumoxytol 3
- Composite moderate-to-severe hypersensitivity reactions: 0.7% for ferric carboxymaltose vs 0.6% for ferumoxytol 3
Important Clinical Context
The evidence consistently demonstrates ferric carboxymaltose has been shown to be safe and efficacious across multiple conditions including CKD, pregnancy, heavy uterine bleeding, inflammatory bowel disease, and congestive heart failure 2. It was the first IV iron formulation associated with fewer cardiovascular events and hospitalizations in heart failure patients 2.
Administration Guidelines to Minimize Risk
Per expert consensus guidelines 2:
- Dilute in 100 mL normal saline
- Infuse over 20-30 minutes
- Start infusion slowly and observe for several minutes before completing the infusion
- Have standard anaphylaxis treatment available (though rarely needed)
- No test dose is required or recommended
Key Caveats
One notable adverse effect unique to ferric carboxymaltose is treatment-emergent hypophosphatemia, which occurred in 38.7% of patients in one trial compared to 0.4% with ferumoxytol 3. For this reason, ferric carboxymaltose should be avoided in patients requiring repeat frequent infusions 2.
A recent study showed ferric derisomaltose had higher rates of mild infusion reactions (10.3%) compared to ferric carboxymaltose (2.4%), though all reactions were mild to moderate 4. This reinforces that ferric carboxymaltose maintains an excellent safety profile among modern IV iron formulations.
Bottom Line for Clinical Practice
Anaphylaxis to Ferinject is exceptionally uncommon at less than 1 in 10,000 administrations, making it the safest IV iron option regarding anaphylaxis risk. The primary concern is not anaphylaxis but rather hypophosphatemia with repeated dosing. Standard precautions with slow infusion initiation and monitoring are sufficient—extensive premedication protocols or test dosing are not warranted based on the evidence.